Asset Details
Do you wish to reserve the book?
BCL-2 mutant B7H6-CAR-T cells synergized with venetoclax for treating small cell lung cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
BCL-2 mutant B7H6-CAR-T cells synergized with venetoclax for treating small cell lung cancer
Do you wish to request the book?
BCL-2 mutant B7H6-CAR-T cells synergized with venetoclax for treating small cell lung cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
BCL-2 mutant B7H6-CAR-T cells synergized with venetoclax for treating small cell lung cancer
2025
Overview
BackgroundPatients with small cell lung cancer (SCLC) generally have a poor prognosis, with an exceptionally high proliferative rate and a strong propensity for early metastasis, indicating the urgent need for novel therapies. The development of chimeric antigen receptor (CAR)s targeting solid tumors is limited owing to the lack of target antigens and low efficacy. In this study, we aimed to discover new targets for SCLC CAR-T therapy and develop CAR-T-based combinational treatment against SCLC in preclinical models.MethodsThe in vitro antitumor activity of B7H6-specific CAR-T cell was evaluated. Venetoclax-resistant B7H6 CAR-T cell were designed and the synergistic effect of venetoclax and B7-H6 CAR-T cells was tested in vitro and in vivo.ResultB7H6 is highly expressed in SCLC tumors. CAR-T cell against B7H6 displayed antigen-specific antitumor efficacy. BCL-2(D103E)-expressing CAR-T cells showed resistance to venetoclax-induced apoptosis. The combinational treatment of venetoclax and BCL-2(D103E)-expressing B7H6-targeting showed potent anti-SCLC effect in vitro and in vivo.ConclusionsOur findings suggest that the combination of BCL-2 mutant-expressing B7H6-targeting CAR-T cells and venetoclax could be a promising novel strategy against B7H6-expressing SCLCs and other solid tumors, providing the foundation for CAR-T cells and proapoptotic small molecules therapy in patients with SCLCs in a clinical trial.
Publisher
BMJ Publishing Group Ltd,BMJ Publishing Group LTD,BMJ Publishing Group
Subject
/ Animals
/ Antigens
/ Bridged Bicyclo Compounds, Heterocyclic - pharmacology
/ Bridged Bicyclo Compounds, Heterocyclic - therapeutic use
/ Cells
/ Chimeric antigen receptor - CAR
/ Female
/ Humans
/ Immune Cell Therapies and Immune Cell Engineering
/ Immunotherapy, Adoptive - methods
/ Lung Neoplasms - drug therapy
/ Mice
/ Mutation
/ Proto-Oncogene Proteins c-bcl-2 - genetics
/ Receptors, Chimeric Antigen - metabolism
/ Small Cell Lung Carcinoma - drug therapy
/ Small Cell Lung Carcinoma - genetics
/ Small Cell Lung Carcinoma - immunology
/ Small Cell Lung Carcinoma - pathology
/ Small Cell Lung Carcinoma - therapy
/ Sulfonamides - therapeutic use
/ Tumors
